1-5 of 5
Authors: Sibylle J Hauske
Save search
Sort by
Journal Article

Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

PDF
Michael Böhm and others
European Heart Journal, Volume 46, Issue 14, 7 April 2025, Pages 1304–1317, https://doi.org/10.1093/eurheartj/ehae938
Published: 04 March 2025
Journal Article

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

PDF
Parminder K Judge and others
Nephrology Dialysis Transplantation, gfae263, https://doi.org/10.1093/ndt/gfae263
Published: 12 November 2024
Journal Article

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

PDF
Kaitlin J Mayne and others
Nephrology Dialysis Transplantation, Volume 40, Issue 4, April 2025, Pages 720–730, https://doi.org/10.1093/ndt/gfae203
Published: 14 September 2024
Journal Article

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

PDF
William G Herrington and others
Clinical Kidney Journal, Volume 13, Issue 4, August 2020, Page 722, https://doi.org/10.1093/ckj/sfz009
Published: 11 February 2019
Journal Article

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

PDF
William G Herrington and others
Clinical Kidney Journal, Volume 11, Issue 6, December 2018, Pages 749–761, https://doi.org/10.1093/ckj/sfy090
Published: 25 October 2018